Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 27, 1033-1069, October 1, 1967]
© 1967 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciaccio, E. I.
Right arrow Articles by Ford, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciaccio, E. I.
Right arrow Articles by Ford, R. T.

Screening Data from Selected in Vitro Enzymatic Systems

I. Standard Test Compounds from the Cancer Chemotherapy National Service Center1

Edward I. Ciaccio2,3, George E. Boxer2, Thomas M. Devlin2,4 and Robert T. Ford2

Seven in vitro enzymatic systems were investigated for the detection of potential cancer chemotherapeutic compounds. The rationale for choosing each enzyme system was that inhibition of the system would have a more adverse effect on the metabolism of the malignant than the normal cell. For each system the validity of the rationale is supported by in vitro evidence, but as yet in vivo evidence is lacking. The following systems were evaluated with a standard series of cancer chemotherapeutic compounds from the CCNSC: lactate, {alpha}-glycerophosphate, and malate dehydrogenases, deoxyribose phosphate aldolase, thymidine phosphorylase, glycolysis, and amino acid incorporation into proteins. These in-vitro screens, as set up, distinguished between specific inhibitors for each system involved and compounds that are either specific inhibitors of other systems or are nonspecific in action. The simple and relatively inexpensive in vitro assays permitted their use as primary screens. The concomitant recording of the data on IBM cards facilitated comparisons of in vitro enzyme systems with each other as well as with data from in vivo animal tests.

1 Supported by contract SA-43-ph-1886 from the Cancer Chemotherapy National Service Center (CCNSC), National Cancer Institute, USPHS.

2 Merck Sharp & Dohme Research Laboratories, Division of Merck & Co., Inc., Rahway, New Jersey, and West Point, Pennsylvania.

3 Present address: Department of Pharmacology, Hahnemann Medical College, Philadelphia, Pennsylvania.

4 Present address: Department of Biological Chemistry, Hahnemann Medical College, Philadelphia, Pennsylvania.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1967 by the American Association for Cancer Research.